Highest-materiality recent filing
Aligos Q2 net loss narrows to $1.5M; cash runway through Q4 2026
Net loss of $1.5M ($0.14 per share) vs $15.9M ($1.53) in Q2 2025; improvement driven by $3.0M warrant fair value gain.
Aligos Q1 net loss $23M; fast track for HBV drug; Amoytop license $25M upfront
Fast Track Designation from FDA for pevifoscorvir sodium for chronic HBV infection.
Exclusive license to develop and commercialize pevifoscorvir sodium for HBV and HBV/HDV in mainland China, Taiwan, Hong Kong, and Macau.
Aligos: Phase 2 HBV interim – DSMB ups HBeAg- sample size to 100; FDA Fast Track granted
DSMB recommended increasing HBeAg- cohort from 74 to 100 participants to optimize power; futility criteria not met.
Aligos reports Q4/FY2025 net loss of $19.9M and $24.2M; cash $77.8M; Phase 2 HBV study progressing
Net loss Q4 2025 $19.9M ($1.91/sh) vs $82.2M ($13.08/sh) in Q4 2024; FY2025 net loss $24.2M ($2.45/sh) vs $131.2M ($20.94/sh) in FY2024.
Aligos Q3 net loss $31.5M; Phase 2 HBV study enrolling; cash $99.1M
Net loss of $31.5M in Q3 2025 vs $19.3M in Q3 2024; diluted EPS loss of $3.04.
Stockholders approved increase in authorized voting common stock from 20M to 100M shares.
Aligos raises >$100M, posts Q1 net income $43.1M; HBV drug Phase 2 to start mid-2025
Cash grew to $137.9M after raising over $100M; expected to fund operations into H2 2026.
Aligos Q4 net loss $82.2M; cash $56.9M; ALG-000184 Phase 2 mid-2025
Q4 net loss $82.2M ($13.08/share) vs $27.9M ($5.50) in Q4 2023; full-year net loss $131.2M vs $87.7M.
Aligos Therapeutics secures $105M private placement to fund Phase 2 hepatitis B study
Gross proceeds ~$105M from sale of 2.1M shares, pre-funded warrants (1.9M shares), and warrants (2.0M shares); closing expected Feb 13, 2025.
Aligos Q3 net loss $19.3M; MASH drug shows up to 46.2% liver fat reduction
Net loss of $19.3M ($3.07 per share) vs $18.0M ($10.37 per share) in Q3 2023.
Aligos Q2 net income $5.1M on warrant revaluation; HERALD topline due early Q4
Cash $94.5M at June 30, down from $135.7M year-end; runway through end of 2025.
Aligos Therapeutics Chief Medical Officer Matthew McClure resigns effective May 9, 2024
Matthew McClure resigned as Chief Medical Officer on May 9, 2024.
Aligos Q1 net loss $34.9M; Phase 2a HERALD study commenced, topline expected Q4 2024
Net loss of $34.9M ($0.22 per share) vs $23.0M ($0.53) in Q1 2023; increase due to non-cash warrant liability charge.
Aligos Q4 net loss $27.9M ($0.22/sh); cash $135.7M; HERALD data expected Q4 2024
Cash and investments $135.7M as of Dec 31, 2023; raised $92.1M in Oct 2023 PIPE; runway through end of 2025.
President Leonid Beigelman resigns; severance includes 6 months salary, 12 months COBRA
Dr. Leonid Beigelman, President, resigned effective Nov 20, 2023; entered into separation agreement.
Aligos Therapeutics President and Board member Leonid Beigelman resigns
Leonid Beigelman resigned from the Board effective Nov 9, 2023.
Aligos Q3 net loss $18.0M ($0.41/shr); raises $92M in October PIPE
Net loss $18.0M ($0.41 per share) vs $18.6M ($0.44) in Q3 2022.
Aligos raises $92M in private placement of shares and warrants
Gross proceeds of $92.15M from sale of 31.4M shares, 81.1M pre-funded warrants, and 56.2M common warrants.
Aligos settles Janssen lawsuit; dismisses counterclaims, releases all parties
Settlement agreement entered Oct 16, 2023 with Janssen Biotech resolving breach of contract and tortious interference claims.
Aligos receives Nasdaq delisting notice for bid price below $1.00
Notice on Sep 5, 2023: stock failed to maintain $1.00 minimum bid for 30 consecutive business days through Sep 1.
Aligos reports Q2 net loss $18.8M; cash $90.8M; NASH program on track for Q4 Phase 2a filing
Net loss $18.8M ($0.43/shr) vs $19.9M ($0.47) in Q2 2022.
Aligos Therapeutics Q1 net loss narrows to $23.0M; NASH and COVID programs on track
Cash, cash equivalents and investments $103.5M as of March 31, 2023, vs $125.8M at Dec 31, 2022.
Aligos reports FY2022 net loss of $96M; provides pipeline updates for NASH, COVID-19, HBV
Net loss FY2022 $96.0M ($2.25/share) vs $128.3M ($3.22) in FY2021; cash $125.8M as of Dec 31, 2022.
Aligos Q1 net loss $35.6M (-$0.84/sh); HBV STOPS/ASO programs terminated; cash $183.2M
Net loss of $35.6M ($0.84 per share) vs $27.7M ($0.74) in Q1 2021; R&D expense rose to $31.7M.
Aligos Therapeutics sued by Janssen over breach of contract, IP ownership
Janssen Biopharma filed complaint in Superior Court of California, San Mateo County on March 26, 2022.
Aligos discontinues hepatitis B drug ALG-020572 after patient hospitalized with ALT flare
Discontinued ALG-020572 (ASO for chronic hepatitis B) after one subject hospitalized and three others experienced ALT flares following 210 mg multiple dosing.
Aligos Q4 2021 net loss $37.7M; cash $205.8M; pipeline advances with 3 candidates in clinic
Net loss Q4 2021 $37.7M ($0.89/share) vs $34.4M in Q4 2020; full year loss $128.3M ($3.22/share).
Aligos halts ALG-010133 development after Phase 1 data show no meaningful HBsAg reduction
Halted development of STOPS drug candidate ALG-010133 for chronic hepatitis B.
Aligos Q3 net loss $33.1M ($0.78 loss per share); clinical programs advance
Net loss $33.1M, EPS $(0.78) vs net loss $33.3M, EPS $(11.00) in Q3 2020.
On January 30, 2025, the Board of Directors of Aligos Therapeutics, Inc. (the “Company”) appointed Lesley Ann Calhoun as the Company’s Chief Operating Officer, effective immediately.
appointed Heather Preston, M.D. and Margarita Chavez, J.D., to the Board to fill the newly created directorships
appointed Heather Preston, M.D. and Margarita Chavez, J.D., to the Board to fill the newly created directorships
The Company intends to appoint to the Audit Committee a third director who satisfies the criteria for service on the Audit Committee no later than 180 days after Mr. Nielsen’s resignation.
On May 9, 2024, Matthew McClure notified Aligos Therapeutics, Inc. (the “Company”) of his resignation from his position as Chief Medical Officer of the Company.
On November 20, 2023, in connection with the previously disclosed resignation of Leonid Beigelman, President of Aligos Therapeutics, Inc. (the “Company”), the Company and Dr. Beigelman entered into a separation and release agreement
On November 9, 2023, Leonid Beigelman resigned from the Board of Directors (the “Board”) of Aligos Therapeutics, Inc. (the “Company”), effective immediately, and from his position as President of the Company, effective as of December 1, 2023.
On November 9, 2023, Leonid Beigelman resigned from the Board of Directors (the “Board”) of Aligos Therapeutics, Inc. (the “Company”), effective immediately, and from his position as President of the Company, effective as of December 1, 2023.
appointed Bridget Martell, M.D., to the Board to fill the newly created directorship resulting from the increase in the number of authorized directors.
Max materiality 0.90 · Median 0.60 · Most common event earnings